CMPS is the stock ticker for Compass Pathways, a company developing a synthetic psilocybin drug called COMP360. With no major trial results or big business deals expected before the end of September 2026, the stock is likely to keep drifting at or below $12.50 per share. Without a concrete reason for large investors to buy in, there's no force pushing the price up.
No near-term catalyst on the calendar; the pilot doesn't move institutional models. Downward drift continues.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →